MA32299B1 - Use of dronedarone to prepare a drug for the treatment of patients with arrhythmia and increased creatinine levels due to dronedarone administration - Google Patents
Use of dronedarone to prepare a drug for the treatment of patients with arrhythmia and increased creatinine levels due to dronedarone administrationInfo
- Publication number
- MA32299B1 MA32299B1 MA33340A MA33340A MA32299B1 MA 32299 B1 MA32299 B1 MA 32299B1 MA 33340 A MA33340 A MA 33340A MA 33340 A MA33340 A MA 33340A MA 32299 B1 MA32299 B1 MA 32299B1
- Authority
- MA
- Morocco
- Prior art keywords
- dronedarone
- arrhythmia
- treatment
- patients
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne l'utilisation de dronédarone, ou de l'un de ses sels pharmaceutiquement acceptables, dans la préparation d'un médicament destiné à traiter des patients souffrant d'arythmie. Lesdits patients présentent une augmentation du niveau de la créatinine due à l'administration de dronédarone, ledit niveau de créatinine augmentant suite à l'initiation d'un traitement à la dronédarone. Ladite augmentation du niveau de créatinine atteint un plateau et est utilisée en tant que nouvelle ligne de base. Cette augmentation est réversible après l'arrêt de la dronédarone.The present invention relates to the use of dronedarone, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating patients suffering from arrhythmia. Said patients have an increase in the level of creatinine due to the administration of dronedarone, said creatinine level increasing following the initiation of a treatment with dronedarone. Said increase in creatinine level reaches a plateau and is used as a new baseline. This increase is reversible after discontinuation of dronedarone.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4873208P | 2008-04-28 | 2008-04-28 | |
EP08290407A EP2116239A1 (en) | 2008-04-29 | 2008-04-29 | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
PCT/IB2009/005930 WO2009133470A2 (en) | 2008-04-28 | 2009-04-28 | Use of dronedarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32299B1 true MA32299B1 (en) | 2011-05-02 |
Family
ID=39680951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33340A MA32299B1 (en) | 2008-04-28 | 2010-11-11 | Use of dronedarone to prepare a drug for the treatment of patients with arrhythmia and increased creatinine levels due to dronedarone administration |
Country Status (27)
Country | Link |
---|---|
US (1) | US20100016423A1 (en) |
EP (2) | EP2116239A1 (en) |
JP (1) | JP2011518872A (en) |
KR (1) | KR20100135853A (en) |
CN (1) | CN102076337A (en) |
AR (1) | AR072954A1 (en) |
AU (1) | AU2009241286A1 (en) |
BR (1) | BRPI0912706A2 (en) |
CA (1) | CA2722815A1 (en) |
CL (1) | CL2009001018A1 (en) |
CO (1) | CO6311076A2 (en) |
DO (1) | DOP2010000327A (en) |
EA (1) | EA201071138A1 (en) |
EC (1) | ECSP10010567A (en) |
IL (1) | IL208900A0 (en) |
MA (1) | MA32299B1 (en) |
MX (1) | MX2010011873A (en) |
NI (1) | NI201000181A (en) |
NZ (1) | NZ588886A (en) |
PA (1) | PA8824601A1 (en) |
PE (1) | PE20091885A1 (en) |
SG (1) | SG188180A1 (en) |
TW (1) | TW200948355A (en) |
UA (1) | UA100883C2 (en) |
UY (1) | UY31790A (en) |
WO (1) | WO2009133470A2 (en) |
ZA (1) | ZA201007727B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2280701A2 (en) | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930149B1 (en) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | ASSOCIATION OF DRONEDARONE WITH AT LEAST ONE DIURETIC, ITS THERAPEUTIC APPLICATION |
FR2959132A1 (en) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | METHODS FOR RISK EVALUATION AND REDUCTION |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
WO2012023024A2 (en) * | 2010-08-17 | 2012-02-23 | Lupin Limited | Controlled release formulations of dronedarone |
RU2456019C1 (en) * | 2011-03-29 | 2012-07-20 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Method for prediction of developing life-threatening ventricular arrhythmias in patients with no structural cardiac changes |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868179A (en) * | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
FR2665444B1 (en) * | 1990-08-06 | 1992-11-27 | Sanofi Sa | AMINO-BENZOFURAN, BENZOTHIOPHENE OR INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM. |
FR2735365B1 (en) * | 1995-06-14 | 1997-09-05 | Sanofi Sa | USE OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURANE DERIVATIVE FOR THE PREPARATION OF A MEDICAMENT USEFUL IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS |
FR2746013B1 (en) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | USE OF ANTIARRHYTHMIC COMPOUNDS IN THE PREVENTION OF POST INFARCT MORTALITY |
FR2764800B1 (en) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURAN DERIVATIVES |
US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
CN1330556A (en) * | 1998-11-06 | 2002-01-09 | G·D·西尔公司 | Combination therepy of angiotensin-converting enzyme inhibor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US6411840B1 (en) * | 1999-11-16 | 2002-06-25 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation |
FR2803846B1 (en) * | 2000-01-17 | 2002-04-05 | Clariant France Sa | 3- (1-HYDROXY-PENTYLIDENE) -5-NITRO-3H-BENZOFURAN-2-ONE, ITS PREPARATION PROCESS AND ITS USE |
GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
FR2817864B1 (en) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | METHANESULFONAMIDO-BENZOFURANE DERIVATIVE, ITS PREPARATION METHOD AND ITS USE AS A SYNTHESIS INTERMEDIATE |
FR2817865B1 (en) * | 2000-12-11 | 2005-02-18 | Sanofi Synthelabo | AMINOALKOXYBENZOYLE DERIVATIVE IN SALT FORM, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF AS SYNTHESIS INTERMEDIATE |
FR2817750B1 (en) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | DRONEDARONE PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION |
EP1347756B1 (en) * | 2000-12-27 | 2006-03-08 | Genzyme Corporation | Controlled release of anti-arrhythmic agents from a biodegradable hydrogel for local application to the heart |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
US20030229007A1 (en) * | 2002-05-30 | 2003-12-11 | Roberto Levi | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia |
DE10237819A1 (en) * | 2002-08-19 | 2004-03-04 | Bayer Ag | 5-Nitrobenzofurane |
US20050004194A1 (en) * | 2003-05-15 | 2005-01-06 | Graves Kurt Chum | Use of organic compounds |
US20060093673A1 (en) * | 2003-06-27 | 2006-05-04 | Coury Arthur J | Controlled release of anti-arrhythmic agents |
WO2005018635A2 (en) * | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
FR2875409B1 (en) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | PHARMACEUTICAL COMPOSITION COMPRISING A SOLID POLYMERIC MATRIX DISPERSION COMPRISING A CONTINUOUS PHASE OF POLYDEXTROSE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE |
GB0611210D0 (en) * | 2006-06-07 | 2006-07-19 | Cambrex Karlskoga Ab | Process |
DE102006035912A1 (en) * | 2006-07-31 | 2008-02-07 | Südzucker AG Mannheim/Ochsenfurt | Use of isomaltulose in regenerative foods |
US20090076137A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dronedarone |
FR2930149B1 (en) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | ASSOCIATION OF DRONEDARONE WITH AT LEAST ONE DIURETIC, ITS THERAPEUTIC APPLICATION |
EP2280701A2 (en) * | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930150B1 (en) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM RATE IN BLOOD |
EP2133075A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion |
EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
EP2153830A1 (en) * | 2008-08-07 | 2010-02-17 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack |
-
2008
- 2008-04-29 EP EP08290407A patent/EP2116239A1/en not_active Withdrawn
-
2009
- 2009-04-27 AR ARP090101485A patent/AR072954A1/en not_active Application Discontinuation
- 2009-04-28 AU AU2009241286A patent/AU2009241286A1/en not_active Abandoned
- 2009-04-28 MX MX2010011873A patent/MX2010011873A/en not_active Application Discontinuation
- 2009-04-28 BR BRPI0912706A patent/BRPI0912706A2/en not_active IP Right Cessation
- 2009-04-28 JP JP2011506799A patent/JP2011518872A/en active Pending
- 2009-04-28 CL CL2009001018A patent/CL2009001018A1/en unknown
- 2009-04-28 CN CN2009801248266A patent/CN102076337A/en active Pending
- 2009-04-28 EP EP09738483A patent/EP2291183A2/en not_active Withdrawn
- 2009-04-28 NZ NZ588886A patent/NZ588886A/en not_active IP Right Cessation
- 2009-04-28 CA CA2722815A patent/CA2722815A1/en not_active Abandoned
- 2009-04-28 EA EA201071138A patent/EA201071138A1/en unknown
- 2009-04-28 WO PCT/IB2009/005930 patent/WO2009133470A2/en active Application Filing
- 2009-04-28 UA UAA201012809A patent/UA100883C2/en unknown
- 2009-04-28 SG SG2013013537A patent/SG188180A1/en unknown
- 2009-04-28 KR KR1020107024051A patent/KR20100135853A/en not_active Application Discontinuation
- 2009-04-28 PE PE2009000576A patent/PE20091885A1/en not_active Application Discontinuation
- 2009-04-29 TW TW098114259A patent/TW200948355A/en unknown
- 2009-04-29 PA PA20098824601A patent/PA8824601A1/en unknown
- 2009-04-29 UY UY0001031790A patent/UY31790A/en not_active Application Discontinuation
- 2009-04-29 US US12/431,830 patent/US20100016423A1/en not_active Abandoned
-
2010
- 2010-10-24 IL IL208900A patent/IL208900A0/en unknown
- 2010-10-26 EC EC2010010567A patent/ECSP10010567A/en unknown
- 2010-10-27 NI NI201000181A patent/NI201000181A/en unknown
- 2010-10-28 DO DO2010000327A patent/DOP2010000327A/en unknown
- 2010-10-28 CO CO10133915A patent/CO6311076A2/en not_active Application Discontinuation
- 2010-10-28 ZA ZA2010/07727A patent/ZA201007727B/en unknown
- 2010-11-11 MA MA33340A patent/MA32299B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2011518872A (en) | 2011-06-30 |
NI201000181A (en) | 2012-03-15 |
KR20100135853A (en) | 2010-12-27 |
PE20091885A1 (en) | 2009-12-31 |
UY31790A (en) | 2009-12-14 |
ECSP10010567A (en) | 2010-11-30 |
DOP2010000327A (en) | 2011-01-31 |
PA8824601A1 (en) | 2009-12-16 |
EP2116239A1 (en) | 2009-11-11 |
IL208900A0 (en) | 2011-01-31 |
CL2009001018A1 (en) | 2011-01-07 |
EA201071138A1 (en) | 2011-06-30 |
UA100883C2 (en) | 2013-02-11 |
CA2722815A1 (en) | 2009-11-05 |
WO2009133470A2 (en) | 2009-11-05 |
US20100016423A1 (en) | 2010-01-21 |
WO2009133470A3 (en) | 2009-12-23 |
NZ588886A (en) | 2013-01-25 |
AU2009241286A1 (en) | 2009-11-05 |
ZA201007727B (en) | 2013-01-30 |
CN102076337A (en) | 2011-05-25 |
AR072954A1 (en) | 2010-10-06 |
BRPI0912706A2 (en) | 2017-06-13 |
CO6311076A2 (en) | 2011-08-22 |
EP2291183A2 (en) | 2011-03-09 |
MX2010011873A (en) | 2011-04-05 |
SG188180A1 (en) | 2013-03-28 |
TW200948355A (en) | 2009-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32299B1 (en) | Use of dronedarone to prepare a drug for the treatment of patients with arrhythmia and increased creatinine levels due to dronedarone administration | |
Grossman et al. | Drug-induced hypertension: an unappreciated cause of secondary hypertension | |
Muto et al. | The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3: 4 trial | |
Troya et al. | Safety and Tolerability: Current Challenges to Antiretroviral Therapy for the Long-Term Management of HIV Infection. | |
MA33533B1 (en) | Pharmaceutical formulations for the treatment of cancer and other diseases or disorders | |
Wei et al. | Transient receptor potential vanilloid 5 mediates Ca2+ influx and inhibits chondrocyte autophagy in a rat osteoarthritis model | |
MA34158B1 (en) | COMBINATIONS CONTAINING SUBSTITUTED 2,3-DIHYDROIMIDAZO {1,2-C] QUINAZOLINE | |
Hao et al. | Astragaloside IV protects RGC-5 cells against oxidative stress | |
Turgut et al. | Hypertension in the elderly: unique challenges and management | |
JP2017014224A (en) | Agent for prevention or treatment of acute-phase pain in herpes zoster-related pain | |
MA33563B1 (en) | 5- (3,4-dichlorophenyl) n (2-hydroxyl-cyclohexyl) -6 (2,2,2-trichloroetoxy) nectanamide and salts used as an agent for raising HDL cholesterol | |
Plotnikov et al. | Relationship between arterial blood pressure and blood viscosity in spontaneously hypertensive rats treated with pentoxifylline | |
JP5727642B2 (en) | A novel treatment method using a centerkin | |
US20170119760A1 (en) | Use of masitinib for the treatment of progressive supranuclear palsy | |
Xu et al. | Remote cyclic compression ameliorates myocardial infarction injury in rats via AMPK-dependent pathway | |
Dong | Protective effects of sinomenine against ankylosing spondylitis and the underlying molecular mechanisms | |
MA54276B1 (en) | MONTELUKAST FOR THE TREATMENT OF HAND OSTEOARTHRITIS | |
MA33979B1 (en) | Piperazine as antimalarial agents | |
RU2012107483A (en) | OTAMIKSABAN FOR TREATMENT OF MYOCARDIAL INFARCTION WITHOUT ST SEGMENT RISE IN ELDERLY PATIENTS AND PATIENTS WITH DISTURBED KIDNEY FUNCTION | |
TW202310842A (en) | Treatment of his hyporesponders | |
Sharpe | The HOPE TIPS: the HOPE study translated into practices | |
Castela et al. | Blue pseudochromhidrosis secondary to topiramate treatment | |
Welston et al. | Gastrointestinal Drugs | |
MX2011006545A (en) | Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies. | |
US20190117669A1 (en) | Methods for Treating NSAID-Induced Cardiovascular, Cerebrovascular, or Renovascular Adverse Events |